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Valproic acid (VPA) can autoinduce its own metabolism. Cases requiring VPA doses >4000mg/day to obtain therapeutic plasma
concentrations, such as these 3 cases, have never been published. Case 1 received VPA for seizures and schizophrenia and had >50
VPA concentrations in 4 years. A high dose of 5,250mg/day of VPA concentrate was prescribed for years but this dose led to an
intoxication when switched to the enterocoated divalproex sodium formulation, requiring a normal dose of 2000mg/day. VPA
metabolic capacity was significantly higher (𝑡 = −9.6; df = 6.3, 𝑝 < 0.001) during the VPA concentrate therapy, possibly due to
autoinduction in that formulation. Case 2 had VPA for schizoaffective psychosis with 10 VPA concentrations during an 8-week
admission. To maintain a VPA level ≥50 𝜇g/mL, VPA doses increased from 1500 to 4000mg/day. Case 3 had tuberous sclerosis and
epilepsy and was followed up for >4 years with 137 VPA concentrations. To maintain VPA concentrations ≥50 𝜇g/mL, VPA doses
increased from 3,375 to 10,500mg/day. In Cases 2 and 3, the duration of admission and the VPA dose were strongly correlated (r
around 0.90; 𝑝 < 0.001) with almost no change after controlling for VPA concentrations, indicating progressive autoinduction that
increased with time.
1. Introduction
Valproic acid (VPA) is a classic antiepileptic drug (AED) and
has been amajor pharmaceutical tool in themanagement of a
range of psychiatric and neurological diseases since the 1960s
[1]. VPA is currently approved in the US for the treatment
of several types of epilepsy, bipolar disorder, and migraine
prophylaxis.Themaximum recommended doses for epilepsy
or bipolar disorder are 60mg/kg/day [2]. It is rare to see
patients taking >4000mg/day. Moreover, therapeutic drug
monitoring (TDM) is frequently used to establish and track
VPA doses. Neurologists frequently use a therapeutic range
of 50–100𝜇g/mL for epilepsy [3]. The therapeutic range in
bipolar disorder is not very well established but some reviews
recommend up to 125 𝜇g/mL for mania [2].
In spite of decades of use, VPA metabolism is not com-
pletely understood [3–8]. VPA primarily undergoes hepatic
metabolism, while <5% is eliminated and unchanged in the
urine. The major mechanisms of hepatic metabolism are the
uridine diphosphate glucuronosyltransferases (UGTs; 40%)
and 𝛽-oxidation as a fatty acid (30%), with the cytochrome
P450 (CYP; including CYP2C9, CYP2C19, and CYP2A6) as a
minor component in the metabolic process. At low doses, 𝛽-
oxidation may be the most important pathway, while at ther-
apeutic doses glucuronidationmay be more important [3–8].
Many UGTs appear to be involved in valproate glucuronida-
tion including UGT1A3, UGT1A4, UGT1A6, UGT1A9, and
UGT2B7, along with the primarily intestinal UGT1A8 and
UGT1A10 [9].
Regarding the potential of causing drug-drug interactions
(DDIs), VPA was traditionally considered to be a moderate
inhibitor of several enzymes including CYP2C9, epoxide
hydroxylase, several UGTs, and the N-glucosidation pathway
of phenobarbital [4]. First, rat studies suggested that VPA
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may autoinduce its own glucuronidation [10]. The first clini-
cal suggestions that VPAmay autoinduce its ownmetabolism
were from studies focused on felbamate [11] and lamotrigine
[12]. More recent studies have been able to demonstrate that
VPA induces (1) its ownmetabolism by inducing 𝛽-oxidation
(prospective study) [13]; (2) CYP3A4 and P-gp gene expres-
sion (in vitro study) [14]; (3) possible UGT1A1 in a patient
taking irinotecan (which has an active metabolite, SN-38,
metabolized by UGT1A1) [15]; (4) aripiprazole metabolism
to a mild degree (prospective study) [16]; (5) olanzapine
metabolism (case series [17], TDM [18], a statistical model of
TDM-DDI studies [19], and a prospective DDI study) [20];
(6) clozapine metabolism (case series [21, 22], a prospective
case report [23], and statistical models of TDM-DDI studies
[24, 25]); and (7) vitamin D metabolism in an in vitro study
[26]. In summary, VPA may be like other AEDs, such as
oxcarbazepine or topiramate, and act as a mild inducer for
some metabolic enzymes and behave as a clinically relevant
inhibitor of other metabolic enzymes.
The following 3 cases, accumulated by the senior author
in the last 20 years of his clinical practice, describe 3 patients
needing high doses of VPA to reach andmaintain therapeutic
concentrations ≥50𝜇g/mL. Recent advances in pharmacoki-
netic knowledge have allowed us to offer a hypothesis about
these patients’ needs for such high VPA doses to reach thera-
peutic concentrations. On February 19, 2015, we conducted a
PubMed search using thewords “valproic acid and (high dose
or high dosage)” limiting them to title or abstract, human
participants, and case reports, which provided 33 articles.
None of these 33 articles described the therapeutic use of
VPA doses >4000mg/day. We decided to publish these cases
because it is very likely that other clinicians have seen similar
patients but did not write about them.
2. Methods
2.1. Clinical Setting. The senior author collected these 3
cases during the last 20 years while working as a clinician
and/or consultant in the public mental health system in
Kentucky, USA. During 8 of those years, he managed a
30-bed treatment-refractory unit for psychotic patients in
a state hospital with approximately 1600 admissions/year.
He acquired Cases 1 and 3 in that setting. For 14 years he
has also acted as a consultant for difficult cases, including
those needing high doses of psychiatric medications in 4
state hospitals for severe mentally ill patients, 4 hospitals
for adults with intellectual disabilities, and 2 nursing homes.
Case 2 was collected as a consultant for another psychiatrist
(third author). In the senior author’s experience, VPA is
probably the most frequently prescribed psychotropic drug
in the public mental health system facilities of Kentucky,
with more than 1000 patients every year treated with VPA
at state facilities. The 3 patients in this paper participated
in pharmacogenetic studies after written informed consent
forms were signed by them and/or their guardians.
2.2. TDM. These 3 cases contain TDM information that was
collected for clinical purposes many years ago. The VPA
TDM was done by immunoassay in the same psychiatric
hospital using the same clinical laboratory at the hospital;
levels were taken as trough concentrations (early AM before
taking medications) and after reaching steady state. The VPA
concentrations were measured in 𝜇g/mL, which is the same
as mg/L.
In the last 10 years, the senior author has increasingly
used the pharmacological concept of concentration-to-dose
ratio (C/D ratio) to study TDM in order to personalize
the prescription of psychiatric medications in psychophar-
macology. The C/D ratio is a measure of the ability to
eliminate the drug and is influenced by genetic, personal, and
environmental factors. Inducers decrease the C/D ratio and
inhibitors increase the C/D ratio. In comparing individuals
taking the same drug, a very low C/D ratio indicates an
individual with very fast metabolism, while a very high C/D
ratio indicates one with very slow metabolism. Each drug is
different and unique and has its own normal ranges for C/D
ratios determined by its own bioavailability and elimination
from the body.
The senior author has used the C/D ratio to interpret
TDM of clobazam [27], clozapine, and risperidone [28].
These 3 drugs, like the majority of drugs used in neuropsy-
chopharmacology, follow linear kinetics. A linear relation-
ship exists between typical doses and plasma concentrations.
This means that the relationship between concentration and
dose is stable; it does not change with different doses and
concentrations, and the drug C/D ratio is constant in the
same patient as long as there are no changes in environmental
or personal variables.
VPA TDM, unfortunately, is a little more complicated
since it does not follow linear kinetics. The relationship
between VPA dose and total concentration is nonlinear; the
concentration does not increase proportionally with the dose
but increases to a lesser extent due to saturable plasma-
protein binding [29]. As the VPA C/D ratio is not constant
and changes with different doses and concentrations, one
needs to further interpret VPA C/D ratios in the context of
a set of concentrations or set of doses.
The senior author has started using VPA C/D ratios in
his teaching and clinical practice in the last 3 years and is
not aware of any published article using them. Therefore, as
the reader may not be familiar with the use of C/D ratios
for valproate VPA, this section provides a short introduction.
Based on experience as a lecturer, the senior author has
figured out that VPA C/D ratios have values too low to be
easily understood by physicians, who do not tend to be par-
ticularly strong in mathematics. To more easily understand
the VPA C/D values, they are also presented with a value
obtained by multiplying by 1000. To understand this, let us
assume that a VPA dose of 2000mg/day provides a total VPA
concentration of 100𝜇g/mL. Therefore the C/D ratio in this
patient is 100/2000 or 0.05. The C/D ratio multiplied by 1000
would be 50, an easier number to grasp.
Next, we can use a published case of VPA toxicity [29]
to explain the interpretation of VPA C/D ratio for clinical
use. To simplify, Table 1 presents only the VPA data including
C/D ratios using total VPA concentrations. This patient has
relatively narrow variations, with a C/D ratio multiplied by
1000 ranging between 112 and 132 (Table 1). These values are
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Table 1: Explaining VPA C/D ratio use with VPA concentrations from a published case [29].
Formulation VPA dose (mg/day) Concentration (𝜇g/mL) C/D ratio C/D ratio × 1000
ECDVNa 1000 112 0.112 112
ECDVNa 750 87 0.116 116
ECDVNa 500 66 0.132 132
ECDVNa 500 64 0.128 128
C/D: concentration-to-dose; ECDVNa: divalproex sodium enterocoated; VPA: valproic acid.
normal in the experience of the senior author. Moreover,
these values follow the usual pattern of VPA C/D ratios. In
low doses, in this case 500mg/day, the C/D ratio multiplied
by 1000 ranged from 128 to 132. In high doses, in this
case 1000mg/day, the C/D ratio multiplied by 1000 was 112,
indicating a faster metabolism at 1000mg/day than at the
500mg/day dose. At higher VPA doses, plasma proteins such
as albumin are saturated by VPA and the percentage of free
(unbound) VPA concentration increases. Since free VPA is
the entity that is metabolized, the higher the percentage
of free concentration is, the faster the VPA is metabolized.
In the experience of the senior author, approximately 90%
of VPA on average is carried by plasmatic proteins and
10% is free at standard therapeutic concentrations. With
higher concentrations, the relative concentrations of free
VPA increase (e.g., 85% bound and 15% free), and with
low concentrations it decreases (e.g., 95% bound and 5%
free). These percentages of free VPA concentration are also
influenced by (1) the plasma concentration of albumin and
other plasmatic proteins, (2) plasma concentrations of some
endogenous compounds that may bind to the proteins (e.g.,
bilirubin), and (3) the presence of other drugs (e.g., aspirin),
which may also compete for plasmatic protein binding [29].
Other examples of VPA C/D ratio are calculated using
published data [30, 31]. A case [30] of a possible VPA adverse
drug reaction (ADR) occurred in a patient who had a VPA
concentration 78𝜇g/mL at a dose of 1500mg/day (C/D ratio
= 0.520 calculated by 78/1500).TheVPAC/D ratio multiplied
by 1000 was 520. In a study of VPA TDM [31], 14 females had
an average VPA concentration of 76 𝜇g/mL with an average
maintenance dose of 629mg/day (C/D ratio = 0.121 calculated
by 76/629) and a VPA C/D ratio multiplied by 1000 of 121. In
the same study, 23 males had an average VPA concentration
of 70 𝜇g/mL with an average maintenance dose of 617mg/day
(C/D ratio = 0.113 calculated by 70/617) with a VPAC/D ratio
multiplied by 1000 of 113.
These 3 cases needing VPA doses >4000mg/day to obtain
VPA therapeutic concentrations had very low mean C/D
ratios multiplied by 1000: in the 20s or lower, possibly due
to VPA autoinduction.
2.3. Scale. For this paper, we have completed the Drug
Interaction Probability Scale (DIPS) [32] for each of the 3
cases.
2.4. Statistics. Available data for each of the 3 cases was
dictated by clinical care; many years later we tried to use
statistical techniques to accommodate the available data and
the questions asked in each case. The Statistical Package for
the Social Sciences (SPSS 22) was used to analyze the data.
In Case 1 an independent sample 𝑡-test compared mean VPA
C/D ratios from the two VPA formulations, one probably
accompanied with autoinduction and the other not. Pearson
correlations between VPA dose and day of admission were
used in Cases 2 and 3 to demonstrate that higher doses
were needed to keep theVPA concentrations therapeutic over
time, which is consistent with a pattern of autoinduction.
Partial correlations were used to demonstrate that VPA
concentrations did not explain the correlation between VPA
dose and day of admission.
3. Case Presentations
3.1. Case 1. A Caucasian male was followed up for more
than 4 years between the ages of 30 and 34 years. His
initial weight was 85Kg. He smoked 10 cigarettes per day.
His psychosis started when he was 12 years old and had
been refractory to treatment for many years at the time
of admission. The patient had three seizures of unknown
origin in the 3 months before coming under the care of
the senior author. Academic neurologists had examined him
at least twice. All tests, including a CT scan of the head,
were negative. After a careful review of all records, it was
the impression of the senior author that at least 1 or 2
of the 3 seizures might have been associated with rapid
withdrawal of high doses of benzodiazepines, particularly
temazepam, used as PRNs. He arrived at the unit with four
antiepileptic medications in his regimen: carbamazepine,
phenytoin, diazepam, and VPA.These medications had been
progressively added by the neurology consultants. The blood
levels of all four of these medications were subtherapeutic.
After several months the senior author was able to change
the regimen to VPA only, without the patient having any
seizures during his long admission. The VPA treatment is
described in detail in Table 2. To avoid too much irrelevant
information, day 164 of admission was selected as day 1
to describe the time-course of VPA treatment. The senior
author was surprised that this patient needed 5250mg/day
of VPA concentrate to get therapeutic VPA concentrations.
After more than 3.5 years of admission, the patient was
finally stabilized on clozapine at 700mg/day, his psychotic
symptoms had greatly improved, and he was getting ready
to be discharged. However, he then began to complain about
the taste of the VPA concentrate in his mouth. With the
assumption of bioequivalent formulations and dosing, the
patient was switched to divalproex sodium at a total daily
dose of 5250mg/day. This led to an unexpected VPA intox-
ication despite the absence of any other medication changes.
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Table 2: VPA C/D ratio in Case 1.
Day VPA dose (mg/day) Concentration (𝜇g/mL) C/D ratio C/D ratio × 1000
Valproic acid concentrate (C/D ratio × 1000: mean ± SD = 151 ± 2.6, range = 10–21)
73 5250 54 0.010 10
144 5250 68 0.013 13
215 5250 68 0.013 13
295 5250 76 0.014 14
705 5250 59 0.011 11
986 5250 66 0.013 13
1196 5250 85 0.016 16
1266 5250 61 0.012 12
1406 5250 75 0.014 14
1756 5250 79 0.015 15
1886 5250 64 0.012 12
2027 5250 64 0.012 12
2388 5250 88 0.017 17
2528 5250 110 0.021 21
2609 5250 86 0.016 16
2809 5250 92 0.018 18
2879 5250 87 0.017 17
30110 5250 87 0.017 17
31910 5250 92 0.018 18
35010 5250 99 0.019 19
37811 5250 85 0.016 16
42012 5250 91 0.017 17
42712 5250 97 0.018 18
43412 5250 87 0.017 17
47012 5250 87 0.017 17
49813 5250 90 0.017 17
55213 5250 95 0.018 18
58213 5250 81 0.015 15
60913 5250 88 0.017 17
6377 5250 80 0.015 15
92814 5250 111 0.021 21
94515 5250 93 0.018 18
97816 5250 78 0.015 15
99817 5250 67 0.013 13
102618 5250 67 0.013 13
105419 5250 66 0.013 13
108219 5250 71 0.014 14
111019 5250 63 0.012 12
114520 5250 69 0.013 13
116621 5250 93 0.018 18
120222 5250 89 0.017 17
120823 5250 75 0.014 14
123624 5250 88 0.017 17
125125 5250 87 0.017 17
EC divalproex sodium (C/D ratio × 1000: mean ± SD = 391 ± 6.3, range = 28–48)
130625 5250 1452 0.028 28
132025 3750 135 0.036 36
133425 3000 127 0.042 42
137325 2500 120 0.048 48
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Table 2: Continued.
Day VPA dose (mg/day) Concentration (𝜇g/mL) C/D ratio C/D ratio × 1000
134825 2000 73 0.037 37
136225 2000 82 0.041 41
137625 2000 78 0.039 39
C/D: concentration-to-dose; EC: enterocoated; VPA: valproic acid.
1According to an independent 𝑡-test calculated with equal variance not assumed, there was significant difference (𝑡 = −9.6; df = 6.3, 𝑝 < 0.001) between these
two means, 15 in VPA concentrate and 39 in divalproex sodium.
2This VPA concentration was measured 4 weeks after switching from VPA concentrate to divalproex sodium. With a high VPA concentration at that time, the
patient showed increased drowsiness.
3Other scheduled oral medications included benztropine 3mg/day, gemfibrozil 1200mg/day, propranolol 80mg/day, and quetiapine 700mg/day.
4Other scheduled oral medications included benztropine 3mg/day, gemfibrozil 1200mg/day, olanzapine 5mg/day, propranolol 80mg/day, and quetiapine
500mg/day.
5Other scheduled oral medications included benztropine 3mg/day, gemfibrozil 1200mg/day, olanzapine 5mg/day, and propranolol 80mg/day.
6Other scheduled oral medications included benztropine 4mg/day, gemfibrozil 1200mg/day, olanzapine 5mg/day, and propranolol 80mg/day.
7Other scheduled oral medications included benztropine 4mg/day, gemfibrozil 1200mg/day, olanzapine 5mg/day, and propranolol 60mg/day.
8Other scheduled oral medications included benztropine 4mg/day, gemfibrozil 1200mg/day, olanzapine 2.5mg/day, and propranolol 30mg/day.
9Other scheduled oral medications included benztropine 4mg/day, gemfibrozil 1200mg/day, olanzapine 2.5mg/day, and propranolol 40mg/day.
10Other scheduled oral medications included benztropine 4mg/day, gemfibrozil 1200mg/day, olanzapine 2.5mg/day, and propranolol 60mg/day.
11Other scheduled oral medications included benztropine 4mg/day, gemfibrozil 1200mg/day, olanzapine 2.5mg/day, and propranolol 120mg/day.
12Other scheduled oral medications included benztropine 4mg/day, clonidine 0.1mg/day, gemfibrozil 1200mg/day, olanzapine 2.5mg/day, and propranolol
60mg/day.
13Other scheduled oral medications included benztropine 4mg/day, gemfibrozil 1200mg/day, olanzapine 2.5mg/day, and propranolol 60mg/day.
14Other scheduled oral medications included benztropine 4mg/day, clozapine 25mg/day, gemfibrozil 1200mg/day, olanzapine 10mg/day, and propranolol
80mg/day.
15Other scheduled oral medications included benztropine 4mg/day, clozapine 300mg/day, gemfibrozil 1200mg/day, olanzapine 10mg/day, and propranolol
80mg/day.
16Other scheduled oral medications included benztropine 4mg/day, clozapine 600mg/day, gemfibrozil 1200mg/day, olanzapine 10mg/day, and propranolol
80mg/day.
17Other scheduled oral medications included benztropine 4mg/day, clozapine 400mg/day, gemfibrozil 1200mg/day, olanzapine 10mg/day, and propranolol
80mg/day.
18Other scheduled oral medications included benztropine 4mg/day, clozapine 700mg/day, gemfibrozil 1200mg/day, olanzapine 10mg/day, and propranolol
80mg/day.
19Other scheduled oral medications included benztropine 4mg/day, clozapine 800mg/day, gemfibrozil 1200mg/day, and propranolol 80mg/day.
20Other scheduled oral medications included atorvastatin 10mg/day, benztropine 4mg/day, clozapine 800mg/day, and propranolol 80mg/day.
21Other scheduled oral medications included atorvastatin 20mg/day, benztropine 4mg/day, clozapine 800mg/day, and propranolol 80mg/day.
22Other scheduled oral medications included atorvastatin 20mg/day, clozapine 700mg/day, docusate 250mg/day, and propranolol 80mg/day.
23Other scheduled oral medications included atorvastatin 20mg/day, benztropine 0.5mg/day, clozapine 700mg/day, docusate 250mg/day, and propranolol
80mg/day.
24Other scheduled oral medications included atorvastatin 20mg/day, benztropine 1mg/day, clozapine 600mg/day, docusate 250mg/day, and propranolol
80mg/day.
25Other scheduled oral medications included atorvastatin 20mg/day, benztropine 1mg/day, clozapine 700mg/day, docusate 250mg/day, and propranolol
80mg/day.
This unexpected outcome left the senior author perplexed
and led him to a brief preliminary publication on VPA
concentrations during the last 3 months of admission [33],
despite having no pharmacological explanation at that time.
Table 2 presents a comprehensive list of the VPA concentra-
tions during most of 4 years, as well as the corresponding
VPA C/D ratios. While the patient was being maintained on
5250mg/day of VPA concentrate for many years, the VPA
C/D ratio multiplied by 1000 yielded values ranging from 10
to 21 with a mean of 15. Divalproex sodium treatment yielded
VPA C/D values which, multiplied by 1000, ranged from 28
to 48, with a mean of 39. The means of 19 and 39 were found
to be significantly different (Table 2, footnote 1), indicating
that the patient’s ability to metabolize VPA was significantly
higher on VPA concentrate than on divalproex sodium.
It is likely that this case presentation reflects the result
of VPA autoinduction only present during VPA concentrate
versus no autoinduction during divalproex sodium use. The
DIPS score was 6, which corresponds to a probable drug
interaction in this case (scored as 1 point each for questions
2, 3, 4, 7, 8, and 9).
3.2. Case 2. Patient 2 was a 66-year-old Caucasian male
nonsmoker with a 26-year history of bipolar disorder and
a history of polysubstance abuse (alcohol and cocaine).
His initial weight was 90Kg. He had 7 prior psychiatric
admissions. On presentation the patient met the criteria
for hypomanic episode with psychotic features. He had a
positive viral panel for hepatitis C and his Hep C RNA PCR
was positive, but his liver function profile and metabolic
panel were unremarkable. Sublingual asenapine 20mg/day,
one of his outpatient medications, was restarted by the third
author on hospital day 2 in addition to VPA 1000mg/day,
which the patient had not received as an outpatient. Other
medications are described in Table 3. The patient did not
experience any signs ofVPA toxicity as the dosewas increased
during his admission. However, he remained hypomanic and
continued to display rapid, pressured speech and flight of
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Table 3: VPA C/D ratio in Case 2.
Day1 Formulation VPA dose1 (mg/day) Concentration (𝜇g/mL) C/D ratio C/D ratio × 10002
All 10 VPA concentrations (C/D ratio × 1000: mean ± SD = 25 ± 5.6, range = 17–33)
8 therapeutic2 VPA concentrations (C/D ratio × 1000: mean ± SD = 24 ± 5.6, range = 17–33)
53 ECDVNa 1500 39 0.026 26
83 ECDVNa 1500 49 0.033 33
144 ECDVNa 2500 61 0.024 24
205 ECDVNa 2500 75 0.030 30
236 ECDVNa 2500 82 0.033 33
297 ECDVNa 3000 77 0.026 26
367 Concentrate 3500 72 0.020 20
417 Concentrate 3500 78 0.022 22
488 Concentrate 4000 73 0.018 18
559 ECDVNa 4000 67 0.017 17
C/D: concentration-to-dose; ECDVNa: enterocoated divalproex sodium; VPA: valproic acid.
1The Pearson correlation between day of admission and VPA dose was 𝑟 = 0.97 (𝑝 < 0.001); VPA dose remained significant in a partial correlation while
controlling for VPA concentration: 𝑟 = 0.96 (𝑝 < 0.001). This is compatible with a progressive autoinduction indicating, at least with dose range, that it was
necessary to increase the dose as the duration lengthened.
250–125𝜇g/mL concentrations are considered therapeutic concentrations. As this patient has 2 nontherapeutic concentrations, it would be better to compare
a priori with other patients using only the VPA therapeutic concentrations. In reality, eliminating the first 2 VPA concentrations, which were subtherapeutic,
made almost no difference.
3Other scheduled oral medications included asenapine 10mg/day, naproxen 1000mg/day, omeprazole 20mg/day, trimethoprim/sulfamethoxazole
1600/320mg/day (for skin breakdown over swollen lower extremities), and trazodone 100mg/day.
4Other scheduled oral medications included asenapine 15mg/day, gabapentin 900mg/day, lisinopril 10mg/day, meloxicam 15mg/day, metoprolol 50mg/day,
omeprazole 20mg/day, trimethoprim/sulfamethoxazole 1600/320mg/day (for skin breakdown over swollen lower extremities), tramadol 150mg/day, and
trazodone 150mg/day.
5Other scheduled oral medications included asenapine 15mg/day, gabapentin 900mg/day, lisinopril 10mg/day, meloxicam 15mg/day, metoprolol 50mg/day,
omeprazole 20mg/day, tramadol 150mg/day, and trazodone 150mg/day.
6Other scheduled oral medications included asenapine 15mg/day, furosemide 40mg/day, gabapentin 900mg/day, lisinopril 10mg/day, metoprolol 50mg/day,
omeprazole 20mg/day, tramadol 150mg/day, and trazodone 150mg/day.
7Other scheduled oral medications included asenapine 15mg/day, furosemide 20mg/day, gabapentin 1200mg/day, lisinopril 10mg/day, metoprolol 50mg/day,
omeprazole 20mg/day, tramadol 200mg/day, and trazodone 150mg/day.
8Other scheduled oral medications included asenapine 15mg/day, furosemide 20mg/day, gabapentin 1200mg/day, metoprolol 50mg/day, omeprazole
20mg/day, tramadol 200mg/day, and trazodone 150mg/day.
9Other scheduled oral medications included asenapine 15mg/day, furosemide 20mg/day, gabapentin 1200mg/day, metoprolol 50mg/day, omeprazole
20mg/day, polyethylene glycol 17 g/day, tramadol 200mg/day, and trazodone 150mg/day.
ideas in addition to increased levels of energy. His VPA
concentrationsweremonitored closelywith gradual increases
in his enterocoated divalproex sodium. Despite increasing
his daily dose and switching to concentrate and then back to
enterocoated divalproex sodium, the dose had to be progres-
sively increased to a total of 4000mg/day to continue to have
a therapeutic response and therapeutic levels. By the time of
discharge, the patient’s mood had become more euthymic.
He was discharged after 10 weeks of inpatient management
in stable condition and with a medication regimen including
VPA at 4000mg/day. This patient was remarkable because,
in order to maintain the therapeutic response and a VPA
level around 70𝜇g/mL, progressively higher doses from 1500
to 4000mg/day were needed to the point that the last VPA
C/D ratio multiplied by 1000 had a value remarkably low
(at 17) while being on a high dose of 4000mg/day and
with a VPA concentration of only 67𝜇g/mL. The mean C/D
ratio multiplied by 1000 was 25 with a range from 17 to 33
(Table 3). As a matter of fact, in spite of the limited number
of VPA concentrations, there was a very strong correlation
(𝑟 = 0.97; 𝑝 < 0.001) between the number of days of
admission and the dose, indicating that, with an increasing
length of admission, the dose increased, and this high value
remained after correcting for VPA concentrations using a
partial correlation (𝑟 = 0.96; 𝑝 < 0.001) (Table 3, footnote
1).This is compatible with a progressive autoinduction; as the
time after admission increased, it was necessary to increase
the VPA dose. The patient was discharged on 4000mg/day;
we do not know what happened after discharge, except that
the patient had no relapses for 2 years after this admission.
Considering the need for higher doses to maintain the
same VPA concentration, the DIPS score was 5 (scoring
1 point each for questions 2, 3, 4, 7, and 8), indicating
a “probable” relationship between VPA and autoinduction
activity.
3.3. Case 3. Patient 3 was a Caucasian male nonsmoker
with a history of tuberous sclerosis, which manifested as
seizure disorder and mental retardation. His initial weight
was 71 Kg. He had been an inpatient at a state psychiatric
hospital for 22 years before the senior author started to
manage his treatment (day 1) when the patient was 48 years
old. Two years later he developed a right renal mass, which
was highly suspicious for renal cell carcinoma on biopsy. It
was followed by a right-sided nephrectomy and cholecystec-
tomy (day 860). However, the final pathology suggested that
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the mass was actually angiomyolipoma, which is common if
there is renal involvement in patients with tuberous sclerosis.
Thorough investigation for left-sided pathology indicated
that his left kidney was functioning well with stable masses
present on CT. From day 1322, the patient progressively
worsened with new-onset episodes of ataxia and confusion.
High clinical suspicion for a brain mass led the senior
author to investigate with MRI. The results indicated that the
patient had a mass in the right lateral ventricle “suggestive
of giant cell astrocytoma” and that “foci of enhancement at
the gray-white junction and numerous signal abnormalities
in the skull suggest the possibility of metastatic disease.”
Giant cell astrocytomas occur in 6–14% of patients with
tuberous sclerosis and should be suspected when there is a
new focal deficit, signs of increased intracranial pressure, or
unexplained behavioral changes. After day 1420, when the
brain tumor was diagnosed, we started trying to reduce the
VPA dose and manage it on the basis of the patient’s comfort
rather than the VPA concentration level.
During the long follow-up of more than 4 years (almost
1500 days) described in Table 4, the patient had therapeutic
levels of phenytoin initially with 500mg/day and at the end
with 400mg/day. VPA showed a completely different pattern,
requiring a progressive increase in the dose to keep VPA
therapeutic concentrations >50𝜇g/mL. On day 1 the VPA
dose was 3375mg/day, on day 400 it was 5000mg/day, on day
943 it was 9000mg/day, and on day 1029 it was 10500mg/day,
which was maintained until it was clear that his physical
deterioration was due to a brain tumor. At that time other
medications were discontinued, only leaving phenytoin and
a lower VPA dose (Table 4).
Despite the necessity of increasing the VPA dose to this
very high dosage, the phenytoin dose remained stable with
normal blood levels in the therapeutic range. This suggests
that the progressive increase in VPA metabolism was not
associated with an increase in phenytoin metabolism. The
VPAC/D ratios in this patient were extremely low, frequently
lower than 10. The mean C/D ratio multiplied by 1000 for 70
therapeutic concentrations was 8 with a range from 5 to 18
(Table 3). As a matter of fact, there was a very strong correla-
tion (𝑟 = 0.97; 𝑝 < 0.001) between the number of days past
admission and the dose, indicating that with an increasing
length of admission, the dose increased, and this significance
remained after correcting for VPA concentrations using a
partial correlation (𝑟 = 0.89; 𝑝 < 0.001) (Table 4, footnote
1). This is compatible with a progressive autoinduction.
Using the DIPS as in the previous cases, the total score
was 5 (scoring 1 point each for questions 2, 3, 4, 7, and 8),
indicating a “probable” relationship between VPA and the
autoinduction of its metabolism.
4. Discussion
4.1. Limitations. These 3 cases reflect 3 extremely challenging
patients who required very high doses of VPA >4000mg/day
to maintain VPA therapeutic levels. As usual in these chal-
lenging cases, the pharmacological data is somewhat limited
since patients were treated with polypharmacy and went
through complex changes in medications. In spite of the data
limitations, we think that these cases need to be published to
acknowledge thatwhile these patients are very rare, they exist.
In support of the above findings, however, the senior author
was closely involved in the treatment of the 3 patients and all
VPA concentrations were measured in the same lab. It is rare
to see publications describe so many large measures of VPA
concentrations.
The data is limited but undeniable and should indicate
to any clinician that these 3 patients needed daily doses of
VPA to get therapeutic VPA concentrations. The second and
greater limitation in analyzing these cases is our interpreta-
tion of the data many years after they were collected—in the
third case, almost 20 years. It has required that much time
to accumulate evidence in the literature to understand what
happened and to realize that VPA may be an inducer; in fact,
it can induce its own metabolism. Therefore, although these
VPA concentrations were collected prospectively and used
to modify VPA doses, they were reviewed retrospectively
to provide the unified hypothesis that it is possible that
these high VPA doses were required because these 3 patients
were unusually sensitive to VPA autoinduction. In retrospect,
after having a possible pharmacological explanation now
after many years, it would have been better to collect more
frequent TDMdata, but what is described is what is available.
Although we acknowledge that the data is limited and our
interpretation is even more limited, we have tried to support
our interpretation through the use of statistical tests and a
validated scale.
4.2. High Doses of VPAMay Be Explained by VPA Autoinduc-
tion. We think these cases contribute to the scarce literature
by indicating that clinicians must be aware that VPA may
behave as an inducer. In Cases 1 and 3, patients with likely
VPA autoinduction presented significant clinical challenges
to the senior author, who had no idea why the patients
required much higher VPA dosages to obtain therapeutic
VPA concentrations. Case 2 was identified only 4 years ago
when the senior author realized that VPA autoinduction was
clinically relevant for some peculiar patients. As a matter of
fact, Case 2 was identified by the third author, who had rarely
seen similar cases. The senior author suggested to her that
these cases were probably explained by autoinduction and
she was able to identify this patient as a candidate for VPA
autoinduction shortly after admission.
The first patient was very challenging, probably the
most challenging patient in the senior author’s career, even
with his more than 25-year history of treating treatment-
refractory patients. The patient metabolized the CYP1A2
drugs clozapine and olanzapine normally but got intoxicated
on clozapine during an infection [34]. He appeared unusual
because he needed 5250mg/day of VPA concentrate for
several years to get therapeutic VPA concentrations. The
senior author had experience in switching many patients
back and forth from VPA concentrate to divalproex sodium
using the same doses and getting similar VPA concentrations.
In fact, the US prescribing information from the drug
manufacturer recommended and continues to recommend
initiating the same total daily doses when converting a
patient from VPA to divalproex sodium. A published study
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Table 4: VPA C/D ratio in Case 3.
Day1 VPA Phenytoin
Formulation Dose1 (mg/day) Concentration (𝜇g/mL) C/D ratio C/D ratio × 1000 Dose (mg/day) Concentration (𝜇g/mL)
All 137 VPA concentrations (C/D ratio × 1000: mean ± SD = 8 ± 3.5, range = 3–20)
70 therapeutic2 VPA concentrations (C/D ratio × 1000: mean ± SD = 9 ± 3.4, range = 5–18)
13 ECDVNa 3375 46 0.014 14 500 15
333 ECDVNa 3375 59 0.017 17 500 18
623 ECDVNa 3375 43 0.013 13 500 16
863 Concentrate 3350 22 0.007 7 500
1173 ECDVNa 3450 43 0.012 12 500 11
1473 ECDVNa 3375 38 0.011 11 500 10
1623 Concentrate 3450 9 0.003 3 500
1743 Concentrate 3450 28 0.008 8 500 18
1773 Concentrate 3450 31 0.009 9 500 18
1893 ECDVNa 3375 36 0.011 11 500
2023 ECDVNa 3750 40 0.011 11 500 10
2083 ECDVNa 4125 40 0.010 10 500 14
2123 ECDVNa 4500 68 0.015 15 500 15
2443 ECDVNa 4500 61 0.014 14 500 15
2743 ECDVNa 4500 67 0.015 15 500 15
3073 ECDVNa 4500 46 0.010 10 500 23
3103 ECDVNa 4500 50 0.011 11 0 23
3133 ECDVNa 4500 39 0.009 9 500 10
3163 ECDVNa 4500 81 0.018 18 500 11
3203 ECDVNa 4500 31 0.007 7 500 15
3243 ECDVNa 4500 46 0.010 10 500 16
3353 ECDVNa 5000 64 0.013 13 500 19
3503 ECDVNa 5000 75 0.015 15 500 24
3983 ECDVNa 5000 52 0.010 10 460 16
4003 ECDVNa 5000 85 0.017 17 460 11
4303 ECDVNa 5000 59 0.012 12 460 16
4393 ECDVNa 5000 65 0.013 13 460 18
4703 ECDVNa 5000 54 0.011 11 460 16
5023 ECDVNa 5000 53 0.011 11 460 20
5304 ECDVNa 5000 77 0.015 15 460 17
5594 ECDVNa 5000 50 0.010 10 460 13
5905 ECDVNa 5000 48 0.010 10 460 12
6216 ECDVNa 5000 37 0.007 7 460 10
6356 ECDVNa 5000 39 0.008 8 460 11
6466 ECDVNa 5250 35 0.007 7 460 13
6817 ECDVNa 5250 37 0.007 7 460 8
7137 ECDVNa 5250 46 0.009 9 460 7
7347 ECDVNa 5250 40 0.008 8 460 10
7627 ECDVNa 6000 53 0.009 9 460 9
7707 ECDVNa 6000 43 0.007 7 460 8
7987 ECDVNa 6000 23 0.004 4 460 9
8067 ECDVNa 6000 32 0.005 5 460 10
8177 ECDVNa 7500 36 0.005 5 200 9
8317 ECDVNa 7500 43 0.006 6 460 5
8387 ECDVNa 7500 47 0.006 6 460 15
8467 ECDVNa 7500 24 0.003 3 460 10
8527 ECDVNa 7500 35 0.005 5 460 8
8607 ECDVNa 7500 51 0.007 7 460
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Table 4: Continued.
Day1 VPA Phenytoin
Formulation Dose1 (mg/day) Concentration (𝜇g/mL) C/D ratio C/D ratio × 1000 Dose (mg/day) Concentration (𝜇g/mL)
8667 ECDVNa 7500 42 0.006 6 460 3
8887 ECDVNa 7500 71 0.009 9 460 20
8907 ECDVNa 7500 81 0.011 11 460 20
9167 ECDVNa 7500 45 0.006 6 460 7
9197 ECDVNa 7500 46 0.006 6 460 7
9297 ECDVNa 8250 43 0.005 5 460
9437 ECDVNa 9000 43 0.005 5 460
9507 ECDVNa 9000 50 0.006 6 460
9577 ECDVNa 9000 75 0.008 8 460
9647 ECDVNa 9000 37 0.004 4 460
9717 ECDVNa 9000 28 0.003 3 460
9727 ECDVNa 9000 44 0.005 5 460 8
9797 ECDVNa 9000 64 0.007 7 460 6
9857 ECDVNa 9000 38 0.004 4 460 9
9897 ECDVNa 9000 50 0.006 6 460 8
9927 ECDVNa 9000 59 0.007 7 460 9
9997 ECDVNa 9000 54 0.006 6 460 6
10147 ECDVNa 9000 35 0.004 4 460 6
10207 ECDVNa 9000 42 0.005 5 460 5
10297 ECDVNa 10500 43 0.004 4 460 7
10357 ECDVNa 10500 102 0.010 10 460 6
10397 ECDVNa 10500 54 0.005 5 460 1
10427 ECDVNa 10500 77 0.007 7 460 6
10567 ECDVNa 10500 120 0.011 11 460 6
10627 ECDVNa 10500 39 0.004 4 460 8
10647 ECDVNa 10500 47 0.004 4 460 7
10707 ECDVNa 10500 56 0.005 5 460 6
10807 ECDVNa 10500 51 0.005 5 460 10
10917 ECDVNa 10500 54 0.005 5 460 11
10987 ECDVNa 10500 63 0.006 6 460 12
11057 ECDVNa 10500 49 0.005 5 460 12
11127 ECDVNa 10500 47 0.004 4 460 8
11197 ECDVNa 10500 51 0.005 5 460 6
11337 ECDVNa 10500 91 0.009 9 460 7
11487 ECDVNa 10500 50 0.005 5 460 13
11637 ECDVNa 10500 40 0.004 4 460 9
11687 ECDVNa 10500 62 0.006 6 460 10
11757 ECDVNa 10500 63 0.006 6 460 13
11827 ECDVNa 10500 110 0.010 10 460 11
11847 ECDVNa 10500 61 0.006 6 460 10
11897 ECDVNa 10500 56 0.005 5 460 10
11967 ECDVNa 14000 133 0.010 10 460 9
12107 ECDVNa 10500 67 0.006 6 460 13
12177 ECDVNa 10500 65 0.006 6 460 14
12247 ECDVNa 10500 87 0.008 8 460 11
12317 ECDVNa 10500 70 0.007 7 460 13
12457 ECDVNa 10500 65 0.006 6 460 15
12527 ECDVNa 10500 97 0.009 9 460 9
12597 ECDVNa 10500 77 0.007 7 460 13
12667 ECDVNa 10500 56 0.005 5 460 12
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Table 4: Continued.
Day1 VPA Phenytoin
Formulation Dose1 (mg/day) Concentration (𝜇g/mL) C/D ratio C/D ratio × 1000 Dose (mg/day) Concentration (𝜇g/mL)
12737 ECDVNa 10500 97 0.009 9 460 14
12807 ECDVNa 10500 60 0.006 6 460 16
12878 ECDVNa 10500 39 0.004 4 460 19
12948 ECDVNa 10500 103 0.010 10 460 15
13018 ECDVNa 10500 48 0.005 5 460 19
13078 ECDVNa 10500 72 0.007 7 460 13
13168 ECDVNa 10500 54 0.005 5 460 13
13228 ECDVNa 10500 71 0.007 7 460 13
13298 ECDVNa 10500 75 0.007 7 460 13
13368 ECDVNa 10500 98 0.009 9 460 12
13448 ECDVNa 10500 93 0.009 9 460 11
13508 ECDVNa 10500 65 0.006 6 460 15
13578 ECDVNa 10500 58 0.006 6 460 23
13648 ECDVNa 10500 73 0.007 7 460 18
13718 ECDVNa 10500 106 0.010 10 460 24
13738 ECDVNa 10500 106 0.010 10 460 20
13788 ECDVNa 10500 89 0.008 8 460 15
13868 ECDVNa 10500 97 0.009 9 460 17
13928 ECDVNa 10500 72 0.007 7 460 21
13938 ECDVNa 10500 87 0.008 8 460 23
13948 ECDVNa 10500 122 0.012 12 230 22
13958 ECDVNa 3500 37 0.011 11 0 20
13998 ECDVNa 10500 130 0.012 12 400 8
14068 ECDVNa 10500 94 0.009 9 400 10
14138 ECDVNa 10500 126 0.012 12 400 12
14208 ECDVNa 10500 108 0.010 10 400 12
14278 ECDVNa 6000 59 0.010 10 400 21
14358 ECDVNa 9000 110 0.012 12 400 5
14408 ECDVNa 9000 86 0.010 10 400 8
14448 ECDVNa 9000 82 0.009 9 400 10
14488 ECDVNa 9000 147 0.016 16 400 10
14547 ECDVNa 7000 93 0.013 13 400 14
14579 ECDVNa 7000 138 0.020 20 400 11
146110 ECDVNa 7000 72 0.010 10 400 13
147011 ECDVNa 7000 101 0.014 14 400 13
1478 ECDVNa 7000 113 0.016 16 400 7
1483 ECDVNa 7000 97 0.014 14 400 6
C/D: concentration-to-dose; ECDVNa: enterocoated divalproex sodium; VPA: valproic acid.
1After day 1420, VPA dose was guided more by physical comfort than VPA concentrations; therefore, these latter days were eliminated to calculate the Pearson
correlation between day of admission and VPA dose, which was 𝑟 = 0.92 (𝑝 < 0.001); VPA dose remained very high in a partial correlation while controlling
for VPA concentration: 𝑟 = 0.89 (𝑝 < 0.001). This is compatible with a progressive autoinduction indicating, at least with dose range, that it was necessary
to increase the dose as the duration lengthened. When all values (including those after day 1420) were used to calculate correlations, the 𝑟 values were, not
surprisingly, slightly reduced both for the total correlation of 𝑟 = 0.83 (𝑝 < 0.001) and the partial correlation of 𝑟 = 0.78 (𝑝 < 0.001).
250–100𝜇g/mL concentrations are considered therapeutic concentrations. As this patient has too many nontherapeutic concentrations, it may be better to
compare with other patients using only the VPA therapeutic concentrations.
3Other scheduled oral medications included benztropine 4mg/day, mesoridazine 200mg/day, lorazepam 6mg/day, and risperidone 12mg/day.
4Other scheduled oral medications included benztropine 4mg/day, lorazepam 6mg/day, and risperidone 12mg/day.
5Other scheduled oral medications included benztropine 4mg/day, lorazepam 6mg/day, and risperidone 4mg/day.
6Other scheduled oral medications included benztropine 4mg/day and lorazepam 6mg/day.
7Other scheduled oral medications included lorazepam 6mg/day.
8Other scheduled oral medications included lorazepam 6mg/day and trazodone 150mg/day.
9Other scheduled oral medications included lorazepam 4mg/day.
10Other scheduled oral medications included lorazepam 3mg/day.
11Other scheduled oral medications included lorazepam 1mg/day.
Case Reports in Psychiatry 11
reported a statistically significant decrease of 14.4% (𝑝 =
0.001) in VPA plasma concentrations upon switching dosage
forms from divalproex sodium to VPA [35]. Therefore, the
senior author expected a minor increase of around 14.4%
in switching from 5250mg/day of VPA concentrate but,
instead, he intoxicated the patient. The VPA concentra-
tion went from the 80s 𝜇g/mL to 145𝜇g/mL and required
halving the dose to 2000mg/day of divalproex sodium to
get VPA concentrations in the 80s𝜇g/mL. In retrospect,
during treatment with VPA concentrate, the VPA C/D ratio
multiplied by 1000 was extremely low, at a mean of 15 and
a range of 10–21, indicating an extraordinarily high capacity
to metabolize VPA.This is compatible with VPA concentrate
inducing its own metabolism. We propose that after 4 weeks
on divalproex sodium the autoinduction was lost and the
patient’s metabolism normalized, with a mean VPA C/D
ratio multiplied by 1000 of 39 and a range of 28 to 48. We
cannot explain why this patient’s VPA concentrate appeared
to induce its own metabolism while divalproex sodium did
not; we assume this patient had some rare genetic variation
that explains his peculiar response.
The second patient had a relatively short admission
(<60 days) but demonstrated a very high and significant
correlation between length of admission and VPA dose. The
final C/D ratio was 17, extremely low. This type of patient is
probably more common than Case 1; his treating psychiatrist,
the third author, has seen several similar cases in her 25-year
practice in patients with severe mental illness including 20
years at this psychiatric hospital.
The third patient probably deserved a Guinness record
since he was treated with 10500mg/day for 400 days and
had a VPA C/D ratio multiplied by 1000 which yielded a
value less than 10 most of the time. We have the impression
that progressive VPA autoinduction explained the need to
go from 3450 to 10500mg/day to achieve and maintain
VPA concentrations >50𝜇g/mL. It is possible that phenytoin
treatment contributed in some way to the facilitation of
VPA autoinduction, since phenytoin is a major inducer and
can displace VPA from plasmatic proteins. It is remarkable
that although increases in VPA dosage were needed to
get therapeutic VPA concentrations, the phenytoin dosage
needed to obtain therapeutic phenytoin concentrations was
relatively stable throughout this time period. Phenytoin doses
ranged from 500mg/day at the beginning to 400mg/day at
the end.This minor reduction in dosage may be explained by
the greaterVPAconcentrations at the end.VPA is an inhibitor
of phenytoin metabolism. Unfortunately, 20 years ago, free
VPA and phenytoin concentrations were not available at this
psychiatric hospital. It would have been important tomeasure
them [29].
4.3. The Pharmacological Mechanism behind VPA Induction.
The induction of metabolic enzymes such as UGTs implies
that the amount of these proteins increases when they
are induced; this is almost always explained by increasing
protein synthesis mediated by the so-called nuclear receptors
(constitutive androstane, estrogen, glucocorticoid receptors,
and pregnane X receptors) or other transcription factors such
as aryl hydrocarbon receptors. The potent AED inducers
(carbamazepine, phenytoin, and phenobarbital) bind to the
pregnane X receptors. Phenytoin and phenobarbital appear
to also bind to the constitutive androstane receptors. VPA is
a less potent inducer but probably works in a similar way.
An in vitro study suggested that VPA might also activate
constitutive androstane receptor and pregnane X receptor
pathways [14].
We think it is possible that these unusual patients needing
very high VPA dosages have unusual genetic variants at the
nuclear receptors, which made them very sensitive to VPA
autoinduction.
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